Intellia Therapeutics, Inc. (LON:0JBU)

Intellia Therapeutics Statistics

Total Valuation

LON:0JBU has a market cap or net worth of GBP 834.14 million. The enterprise value is 444.20 million.

Market Cap	834.14M
Enterprise Value	444.20M

Important Dates

The last earnings date was Thursday, August 7, 2025.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	107.35M
Shares Outstanding	n/a
Shares Change (YoY)	+10.38%
Shares Change (QoQ)	+0.22%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	102.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	21.62
PB Ratio	1.60
P/TBV Ratio	1.60
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.27
EV / Sales	11.38
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.44

Financial Position

The company has a current ratio of 5.19, with a Debt / Equity ratio of 0.14.

Current Ratio	5.19
Quick Ratio	4.93
Debt / Equity	0.14
Debt / EBITDA	n/a
Debt / FCF	-0.24
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -56.95% and return on invested capital (ROIC) is -33.77%.

Return on Equity (ROE)	-56.95%
Return on Assets (ROA)	-30.62%
Return on Invested Capital (ROIC)	-33.77%
Return on Capital Employed (ROCE)	-63.73%
Revenue Per Employee	95,733
Profits Per Employee	-869,711
Employee Count	403
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -55.62% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-55.62%
50-Day Moving Average	11.02
200-Day Moving Average	10.64
Relative Strength Index (RSI)	44.38
Average Volume (20 Days)	17,193

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.74

Income Statement

In the last 12 months, LON:0JBU had revenue of GBP 38.58 million and -350.49 million in losses. Loss per share was -3.42.

Revenue	38.58M
Gross Profit	-282.65M
Operating Income	-373.72M
Pretax Income	-350.49M
Net Income	-350.49M
EBITDA	-366.32M
EBIT	-373.72M
Loss Per Share	-3.42

Balance Sheet

The company has 335.50 million in cash and 74.88 million in debt, giving a net cash position of 385.33 million.

Cash & Cash Equivalents	335.50M
Total Debt	74.88M
Net Cash	385.33M
Net Cash Per Share	n/a
Equity (Book Value)	522.06M
Book Value Per Share	4.96
Working Capital	292.29M

Cash Flow

In the last 12 months, operating cash flow was -305.52 million and capital expenditures -2.36 million, giving a free cash flow of -307.88 million.

Operating Cash Flow	-305.52M
Capital Expenditures	-2.36M
Free Cash Flow	-307.88M
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	-968.69%
Pretax Margin	-908.48%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LON:0JBU does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.38%
Shareholder Yield	n/a
Earnings Yield	-42.02%
FCF Yield	-36.91%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0JBU has an Altman Z-Score of -0.27 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.27
Piotroski F-Score	3